Tirzepatide Research: The 2024-2025 Findings
What did Tirzepatide research measure first?
A direct 2025 study tracked weight for 72 weeks. Tirzepatide brought the larger average drop [5]. SURMOUNT-5 is the strongest recent test against another weekly shot.
Peptide is the medical word for a short, protein-like chain. Tirzepatide has a 39-amino-acid chain. The count won’t predict your result. Both gut hormones are copied by the drug. One is GLP-1, which can lower hunger. Earlier medicines copied only GLP-1.
More than ten large human trials tested weight and blood sugar. In type 2 diabetes, SURPASS found tirzepatide matched or beat several sugar-lowering drugs. That doesn’t mean every person did better.
The 2024-2025 work also separated lost pounds into fat and muscle. It checked daily movement and heart health too. You’ll see the best finding first, then each limit.
You’ll get guidance, not a forecast, because these studies can’t know you. They won’t choose your care, and they don’t know your other medicines. You’ll need your own follow-up because you aren’t getting a promise, and that’s the useful limit.
What is Tirzepatide made to do?
Tirzepatide has a 39-amino-acid chain. Think of amino acids as links also found in proteins. Scientists built the drug from one gut hormone. They attached a fatty acid, a small fat-based chain [1]. That attachment keeps one shot in your blood for a week.
Natural GLP-1 and the other gut hormone leave your blood quickly. The fatty acid slows tirzepatide’s exit. A chemical formula won’t tell you how your body will respond.
Researchers first put the drug on cells in a dish. Those cells reacted to both hormones, including GLP-1 [2]. More dish work showed that one drug could mimic the pair [17]. A 2025 review found much the same [26]. None of those tests measured your hunger, sugar, weight, or safety.
In you, copied GLP-1 slows the stomach and lowers hunger. It also holds down another hormone that pushes blood sugar upward. The added gut hormone may curb hunger and change how fat uses energy. A 2025 review says both actions may curb eating and raise calorie use [27]. Human trials give you the sounder answer.
The fatty acid is why the shot lasts longer.
What did Tirzepatide vs semaglutide studies find?
Semaglutide is another drug for type 2 diabetes and weight care. Each drug is given once per week. Two head-to-head studies give the clearest comparison.
SURPASS-2 followed 1879 adults with type 2 diabetes in a 40-week study in 2021. This was phase 3, a large late study after early safety work. It tested tirzepatide at 5, 10, and 15 mg. A blood test showed average sugar over three months. It fell by 2.01, 2.24, and 2.30 percentage points with tirzepatide. The other 1 mg weekly shot brought a fall of 1.86 points. Tirzepatide did at least as well at every amount. At the low, middle, and top amount, users lost -1.9, -3.6, and -5.5 kg more. Each minus sign means more loss with tirzepatide [3].
SURMOUNT-5 followed 751 adults with obesity, not type 2 diabetes, in 2025. Each person used the highest amount they could bear. Tirzepatide users took 10 or 15 mg. The other shot used 1.7 or 2.4 mg. At 72 weeks, average change was -20.2% with tirzepatide. It was -13.7% with the other drug. The study ended at 72 weeks. The minus signs mean weight fell. The tirzepatide loss was clearly larger. More users lost 10%, 15%, 20%, or 25%. Their waists also shrank more [5].
A weaker study compared results from separate trials. Researchers used math to line up groups by sex, race, and starting health. It compared tirzepatide 10 mg and 15 mg with a 50 mg pill. At 10 mg, users lost -4.48% more. At 15 mg, they lost -5.59% more. It also favored tirzepatide at the 5%, 10%, 15%, and 20% marks [29]. The drugs weren’t tested head to head in one trial.
Your doctor can’t choose from weight numbers alone. You’ll need benefits and harms weighed.
What did SURMOUNT find about Tirzepatide and weight?
SURMOUNT-1 followed 2539 adults for 72 weeks in a 72-week phase 3 study in 2022. Early safety work came first. Everyone had obesity. Body mass index sets weight beside height. It was 30 or more, or 27 if weight was tied to another illness. No one had type 2 diabetes. At 5 mg, average change was -15.0%. It was -19.5% at 10 mg and -20.9% at 15 mg. Placebo brought -3.1% [4]. Every minus sign means weight fell. Stomach and bowel trouble peaked as amounts rose.
The 2025 SURMOUNT-1 follow-up watched adults with obesity and prediabetes. Prediabetes means sugar is high, but diabetes hasn’t begun. Its report came out in 2025. Weight stayed lower, and fewer people developed type 2 diabetes [28]. The finding fits people like those studied.
SURMOUNT-3 began in 2023 after a 12-week food and activity plan. Everyone lost at least 5% before taking the drug. Tirzepatide then brought another -18.4% change from that new start. The minus sign means another drop. Placebo users gained +2.5% over 72 weeks [30].
The body scan. A 2025 study scanned 160 people from SURMOUNT-1. It separated fat from everything else, including muscle. About 75% of the lost weight was fat. The other 25% was other tissue [10]. Across a wider review, half the studies put muscle below 28% of lost weight, and half put it above [15]. A bathroom scale can’t show that split.
Start with your health when looking for the closest group.
What else have Tirzepatide studies found?
Work from 2024-2025 asked about illness beyond weight and blood sugar.
Sleep apnea. In 2024, one study enrolled two groups with serious sleep apnea and obesity. Without a breathing machine, breathing stopped or grew shallow 25.3 fewer times each hour. With a breathing machine, it happened 29.3 fewer times each hour. Placebo groups improved by about 5 times each hour over 52 weeks. That use later won FDA approval [24].
Serious fatty liver disease. Another 2024 study involved people with fat, swelling, and scars in the liver. The illness cleared in more tirzepatide users. Their liver scars didn’t worsen [25].
A form of heart failure. The 2025 heart study enrolled adults with obesity. They had heart failure, yet their hearts pumped the usual share of blood. Tirzepatide cut heart-failure problems compared with placebo [23].
One large review in 2025 joined 56 trials with 60,307 people. Tirzepatide and semaglutide, another weight drug, each led to more than 10% loss against placebo. Tirzepatide also helped sleep apnea and fatty liver disease [11]. The catch is that the studies differed.
Daily movement and well-being. A review published in 2026 included papers found by its last search, also in 2026. One form had 36 questions about pain, walking, work, and daily health. The other asked how weight affected daily life. People using tirzepatide scored better on both forms. Results appeared at both 10 and 15 mg. Reviewers were 95% sure the first form showed some gain and 95% sure the second did too. Yet the studies disagreed on how large the gains were [31]. The review can’t tell whether you’d notice one.
Heart safety. A 2025 study compared tirzepatide with an older drug. The adults had type 2 diabetes and artery disease. Tirzepatide did no worse at preventing heart attack, stroke, or death from heart trouble [32]. It didn’t prove the drug was better. The result came from a high-risk group.
You know your heart, liver, and daily health. Your doctor needs what you’ve seen.